A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)

Powles, T., Brown, J., Larkin, J. et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534

Metadata

Authors/Creators:
  • Powles, T.
  • Brown, J.
  • Larkin, J.
  • Jones, R.
  • Ralph, C.
  • Hawkins, R.
  • Chowdhury, S.
  • Boleti, E.
  • Bhal, A.
  • Fife, K.
  • Webb, A.
  • Crabb, S.
  • Geldart, T.
  • Hill, R.
  • Dunlop, J.
  • Hall, P.E.
  • McLaren, D.
  • Ackerman, C.
  • Beltran, L.
  • Nathan, P.
Copyright, Publisher and Additional Information: © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an author produced version of a paper subsequently published in Annals of Oncology. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: renal cell carcinoma; tyrosine kinase inhibitor; biomarker; SRC; VEGF
Dates:
  • Published: May 2016
  • Published (online): 21 January 2016
  • Accepted: 6 January 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 13 Jul 2016 15:47
Last Modified: 14 Apr 2017 02:51
Published Version: http://dx.doi.org/10.1093/annonc/mdw014
Status: Published
Publisher: Oxford University Press
Refereed: Yes
Identification Number: https://doi.org/10.1093/annonc/mdw014
Related URLs:

Share / Export

Statistics